Xinda Biological (01801) reported over 8.2 billion yuan in product revenue for the first half of the year, a year-on-year increase of more than 55%.

Zhitong Financial APP news, Innovent Biologics (01801) announced that in the first half of 2026, the companys product revenue reached over RMB 8.2 billion, an increase of more than 55% year-on-year. Among them, the companys product revenue in the second quarter exceeded RMB 4.3 billion, a year-on-year growth of about 60%. This strong performance fully demonstrates the continued effectiveness of the company's "dual-driver" strategy. The comprehensive product line maintains strong growth, with core products such as Xin'ermei (masitinib injection), Xinbile (tulexizumab injection), and Xinbimin (tizotumab vedotin N01 injection) performing exceptionally well, becoming important drivers of revenue growth. At the same time, the company's leadership advantage in the oncology field remains solid, with the market penetration of five newly included tyrosine kinase inhibitors (TKIs) in the National Reimbursement Drug List (NRDL) continuously improving, accelerating revenue growth. In addition, the company successfully expanded its strategy into the commercialization of breast cancer treatment, establishing a commercial cooperation with Eli Lilly for Verzig (abemaciclib tablets) in mainland China, laying a solid foundation for the company's subsequent breast cancer pipeline development and market expansion.